Prospects for pharmacological targeting of pseudokinases


Futreal, P. A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177–183 (2004).


Wu, P., Nielsen, T. E. & Clausen, M. H. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36, 422–439 (2015).


Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007).


Creixell, P. et al. Kinome-wide decoding of network-attacking mutations rewiring cancer signaling. Cell 163, 202–217 (2015).


Chang, M. T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155–163 (2016).


Nieto, P. et al. A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature 548, 239–243 (2017).


Wan, P. T. C. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867 (2004).


Garnett, M. J. et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963–969 (2005).


Yao, Z. et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548, 234–238 (2017).


Jacobsen, A. V. & Murphy, J. M. The secret life of kinases: insights into non-catalytic signalling functions from pseudokinases. Biochem. Soc. Trans. 45, 665–681 (2017).


Kung, J. E. & Jura, N. Structural basis for the non-catalytic functions of protein kinases. Structure 24, 7–24 (2016).


Shaw, A. S., Kornev, A. P., Hu, J., Ahuja, L. G. & Taylor, S. S. Kinases and pseudokinases: lessons from RAF. Mol. Cell. Biol. 34, 1538–1546 (2014).


Berger, S. B. et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J. Immunol. 192, 5476–5480 (2014).


Newton, K. et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 343, 1357–1360 (2014).


Mandal, P. et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol. Cell 56, 481–495 (2014).


Camps, M. et al. Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science 280, 1262–1265 (1998).


Zhou, B. et al. Mapping ERK2-MKP3 binding interfaces by hydrogen/deuterium exchange mass spectrometry. J. Biol. Chem. 281, 38834–38844 (2006).


Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).


Boudeau, J., Miranda-Saavedra, D., Barton, G. J. & Alessi, D. R. Emerging roles of pseudokinases. Trends Cell Biol. 16, 443–452 (2006).


Reiterer, V., Eyers, P. A. & Farhan, H. Day of the dead: pseudokinases and pseudophosphatases in physiology and disease. Trends Cell Biol. 24, 489–505 (2014).


Bailey, F. P., Byrne, D. P., McSkimming, D., Kannan, N. & Eyers, P. A. Going for broke: targeting the human cancer pseudokinome. Biochem. J. 465, 195–211 (2015).


Caenepeel, S., Charydczak, G., Sudarsanam, S., Hunter, T. & Manning, G. The mouse kinome: discovery and comparative genomics of all mouse protein kinases. Proc. Natl Acad. Sci. USA 101, 11707–11712 (2004).


Castells, E. & Casacuberta, J. M. Signalling through kinase-defective domains: the prevalence of atypical receptor-like kinases in plants. J. Exp. Bot. 58, 3503–3511 (2007).


Bemm, F., Schwarz, R., Förster, F. & Schultz, J. A kinome of 2600 in the ciliate Paramecium tetraurelia. FEBS Lett. 583, 3589–3592 (2009).


Goldberg, J. M. et al. The dictyostelium kinome—analysis of the protein kinases from a simple model organism. PLOS Genet. 2, e38 (2006).


Peixoto, L. et al. Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses. Cell Host Microbe 8, 208–218 (2010).


Hunter, T. & Manning, G. in Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease (eds Wheeler, D. L. & Yarden, Y.) 1–15 (Springer, New York, NY, 2015).


Wilson, L. J. et al. New perspectives, opportunities, and challenges in exploring the human protein kinome. Cancer Res. 78, 15–29 (2018).


Byrne, D. P., Foulkes, D. M. & Eyers, P. A. Pseudokinases: update on their functions and evaluation as new drug targets. Future Med. Chem. 9, 245–265 (2017).


Jura, N., Shan, Y., Cao, X., Shaw, D. E. & Kuriyan, J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl Acad. Sci. USA 106, 21608–21613 (2009).


Monsey, J., Shen, W., Schlesinger, P. & Bose, R. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J. Biol. Chem. 285, 7035–7044 (2010).


Littlefield, P. et al. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci. Signal. 7, ra114 (2014).


Zhang, X., Gureasko, J., Shen, K., Cole, P. A. & Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137–1149 (2006).


Liu, L. et al. Regulation of kinase activity in the Caenorhabditis elegans EGF receptor, LET-23. Structure 26, 270–281 (2018).


Zhang, K. et al. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271, 3884–3890 (1996).


Hellyer, N. J., Kim, M. S. & Koland, J. G. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J. Biol. Chem. 276, 42153–42161 (2001).


Erjala, K. et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin. Cancer Res. 12, 4103–4111 (2006).


Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).


Sergina, N. V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437–441 (2007).


Miller, T. W. et al. Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res. 69, 4192–4201 (2009).


Desbois-Mouthon, C. et al. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin. Cancer Res. 15, 5445–5456 (2009).


Jeong, E. G. et al. ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int. J. Cancer 119, 2986–2987 (2006).


Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–1075 (2008).


Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869–873 (2010).


Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157–1160 (2011).


Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).


Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).


Jaiswal, B. S. et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23, 603–617 (2013).


Mishra, R. et al. Activating HER3 mutations in breast cancer. Oncotarget 9, 27773–27788 (2018).


Riethmacher, D. et al. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature 389, 725–730 (1997).


Massa, R. et al. Overexpression of ErbB2 and ErbB3 receptors in Schwann cells of patients with Charcot-Marie-tooth disease type 1A. Muscle Nerve 33, 342–349 (2006).


Kanazawa, T. et al. Schizophrenia is not associated with the functional candidate gene ERBB3: results from a case-control study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 113–116 (2007).


Watanabe, Y. et al. No association between the ERBB3 gene and schizophrenia in a Japanese population. Neurosci. Res. 57, 574–578 (2007).


Al-Shawi, R., Ashton, S. V., Underwood, C. & Simons, J. P. Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev. Genes Evol. 211, 161–171 (2001).


Fukuda, T. et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc. Natl Acad. Sci. USA 105, 3047–3052 (2008).


Oishi, I. et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 8, 645–654 (2003).


Yu, J. et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J. Clin. Invest. 126, 585–598 (2016).


Gentile, A., Lazzari, L., Benvenuti, S., Trusolino, L. & Comoglio, P. M. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 71, 3132–3141 (2011).


Gentile, A., Lazzari, L., Benvenuti, S., Trusolino, L. & Comoglio, P. M. The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. Int. J. Cancer 135, 2305–2316 (2014).


Yamaguchi, T. et al. NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 21, 348–361 (2012).


Morioka, K. et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 100, 1227–1233 (2009).


Wright, T. M. et al. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene 28, 2513–2523 (2009).


Lara, E. et al. Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer. Mol. Cancer 9, 170 (2010).


Geng, M. et al. Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. World J. Gastroenterol. 18, 1328–1338 (2012).


Mikels, A. J. & Nusse, R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLOS Biol. 4, e115 (2006).


Oldridge, M. et al. Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B. Nat. Genet. 24, 275–278 (2000).


Schwabe, G. C. et al. Distinct mutations in the receptor tyrosine kinase gene ROR2 cause brachydactyly type B. Am. J. Hum. Genet. 67, 822–831 (2000).


Afzal, A. R. et al. Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by mutation of ROR2. Nat. Genet. 25, 419–422 (2000).


van Bokhoven, H. et al. Mutation of the gene encoding the ROR2 tyrosine kinase causes autosomal recessive Robinow syndrome. Nat. Genet. 25, 423–426 (2000).


Schwabe, G. C. et al. Ror2 knockout mouse as a model for the developmental pathology of autosomal recessive Robinow syndrome. Dev. Dyn. 229, 400–410 (2004).


Peradziryi, H. et al. PTK7/Otk interacts with Wnts and inhibits canonical Wnt signalling. EMBO J. 30, 3729–3740 (2011).


Martinez, S. et al. The PTK7 and ROR2 protein receptors interact in the vertebrate WNT/planar cell polarity (PCP) pathway. J. Biol. Chem. 290, 30562–30572 (2015).


Wehner, P. et al. RACK1 is a novel interaction partner of PTK7 that is required for neural tube closure. Development 138, 1321–1327 (2011).


Puppo, F. et al. Protein tyrosine kinase 7 has a conserved role in Wnt/β-catenin canonical signalling. EMBO Rep. 12, 43–49 (2011).


Hayes, M. et al. ptk7 mutant zebrafish models of congenital and idiopathic scoliosis implicate dysregulated Wnt signalling in disease. Nat. Commun. 5, 4777 (2014).


Wang, M. et al. Role of the planar cell polarity gene protein tyrosine kinase 7 in neural tube defects in humans. Birth Defects Res. A Clin. Mol. Teratol. 103, 1021–1027 (2015).


Mossie, K. et al. Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family. Oncogene 11, 2179–2184 (1995).


Chen, R. et al. A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma. Cancer Res. 74, 2892–2902 (2014).


Gärtner, S. et al. PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement. PLOS ONE 9, e84472 (2014).


Wang, H. et al. PTK7 protein is decreased in epithelial ovarian carcinomas with poor prognosis. Int. J. Clin. Exp. Pathol. 7, 7881–7889 (2014).


Easty, D. J. et al. Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. Int. J. Cancer 71, 1061–1065 (1997).


Lu, W., Yamamoto, V., Ortega, B. & Baltimore, D. Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. Cell 119, 97–108 (2004).


Keeble, T. R. et al. The Wnt receptor Ryk is required for Wnt5a-mediated axon guidance on the contralateral side of the corpus callosum. J. Neurosci. 26, 5840–5848 (2006).


Liu, Y. et al. Ryk-mediated Wnt repulsion regulates posterior-directed growth of corticospinal tract. Nat. Neurosci. 8, 1151–1159 (2005).


Liu, Y. et al. Repulsive Wnt signaling inhibits axon regeneration after CNS injury. J. Neurosci. 28, 8376–8382 (2008).


Katso, R. M. et al. Overexpression of H-Ryk in epithelial ovarian cancer: prognostic significance of receptor expression. Clin. Cancer Res. 6, 3271–3281 (2000).


Saharinen, P., Takaluoma, K. & Silvennoinen, O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20, 3387–3395 (2000).


Saharinen, P. & Silvennoinen, O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277, 47954–47963 (2002).


Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779–1790 (2005).


Walters, D. K. et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10, 65–75 (2006).


Flex, E. et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 205, 751–758 (2008).


Jeong, E. G. et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin. Cancer Res. 14, 3716–3721 (2008).


Lupardus, P. J. et al. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl Acad. Sci. USA 111, 8025–8030 (2014).


Shan, Y. et al. Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. Nat. Struct. Mol. Biol. 21, 579–584 (2014).


Chen, M. et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol. Cell. Biol. 20, 947–956 (2000).


Li, Z. et al. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent. J. Immunol. 190, 2335–2344 (2013).


Murphy, J. M. et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443–453 (2013).


Wang, H. et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol. Cell 54, 133–146 (2014).


Hildebrand, J. M. et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc. Natl Acad. Sci. USA 111, 15072–15077 (2014). This study identifies an ATP-competitive compound that binds to the pseudoactive site of MLKL and inhibits necroptosis.


Linkermann, A. & Green, D. R. Necroptosis. N. Engl. J. Med. 370, 455–465 (2014).


Ting, A. T., Pimentel-Muiños, F. X. & Seed, B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J. 15, 6189–6196 (1996).


Rajakulendran, T. et al. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542–545 (2009).


Hu, J. et al. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc. Natl Acad. Sci. USA 108, 6067–6072 (2011).


Lavoie, H. et al. MEK drives BRAF activation through allosteric control of KSR proteins. Nature 554, 549–553 (2018).


Lozano, J. et al. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. Cancer Res. 63, 4232–4238 (2003).


Kortum, R. L. & Lewis, R. E. The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol. Cell. Biol. 24, 4407–4416 (2004).


Nguyen, A. et al. Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. Mol. Cell. Biol. 22, 3035–3045 (2002).


Costanzo-Garvey, D. L. et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab. 10, 366–378 (2009).


Revelli, J.-P. et al. Profound obesity secondary to hyperphagia in mice lacking kinase suppressor of ras 2. Obesity (Silver Spring) 19, 1010–1018 (2011).


Pearce, L. R. et al. KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation. Cell 155, 765–777 (2013).


Tagliabracci, V. S. et al. Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science 336, 1150–1153 (2012).


Cui, J. et al. A secretory kinase complex regulates extracellular protein phosphorylation. eLife 4, e06120 (2015).


Ohyama, Y. et al. FAM20A binds to and regulates FAM20C localization. Sci. Rep. 6, 27784 (2016).


O’Sullivan, J. et al. Whole-exome sequencing identifies FAM20A mutations as a cause of amelogenesis imperfecta and gingival hyperplasia syndrome. Am. J. Hum. Genet. 88, 616–620 (2011).


Simpson, M. A. et al. Mutations in FAM20C are associated with lethal osteosclerotic bone dysplasia (Raine syndrome), highlighting a crucial molecule in bone development. Am. J. Hum. Genet. 81, 906–912 (2007).


Tagliabracci, V. S. et al. A single kinase generates the majority of the secreted phosphoproteome. Cell 161, 1619–1632 (2015).


Dedhia, P. H. et al. Differential ability of Tribbles family members to promote degradation of C/EBPα and induce acute myelogenous leukemia. Blood 116, 1321–1328 (2010).


Qi, L. et al. TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism. Science 312, 1763–1766 (2006).


Keeshan, K. et al. Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. Blood 116, 4948–4957 (2010).


Jamieson, S. A. et al. Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1. Sci. Signal. 11, eaau0597 (2018). This study demonstrates that substrate binding alters the conformation of the TRIB1 pseudokinase domain, providing evidence that pseudokinases can undergo conformational transitions similar to those observed for active kinases.


Eyers, P. A., Keeshan, K. & Kannan, N. Tribbles in the 21st century: the evolving roles of Tribbles pseudokinases in biology and disease. Trends Cell Biol. 27, 284–298 (2016).


Yoshida, A., Kato, J.-Y., Nakamae, I. & Yoneda-Kato, N. COP1 targets C/EBPα for degradation and induces acute myeloid leukemia via Trib1. Blood 122, 1750–1760 (2013).


Bauer, R. C., Yenilmez, B. O. & Rader, D. J. Tribbles-1: a novel regulator of hepatic lipid metabolism in humans. Biochem. Soc. Trans. 43, 1079–1084 (2015).


Yokoyama, T. et al. Trib1 links the MEK1/ERK pathway in myeloid leukemogenesis. Blood 116, 2768–2775 (2010).


Izrailit, J., Berman, H. K., Datti, A., Wrana, J. L. & Reedijk, M. High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFβ pathways as fundamental Notch regulators in breast cancer. Proc. Natl Acad. Sci. 110, 1714–1719 (2013).


Du, K., Herzig, S., Kulkarni, R. N. & Montminy, M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300, 1574–1577 (2003).


Liew, C. W. et al. The pseudokinase tribbles homolog 3 interacts with ATF4 to negatively regulate insulin exocytosis in human and mouse β cells. J. Clin. Invest. 120, 2876–2888 (2010).


Zareen, N. et al. A feed-forward loop involving Trib3, Akt and FoxO mediates death of NGF-deprived neurons. Cell Death Differ. 20, 1719–1730 (2013).


Aimé, P. et al. Trib3 is elevated in Parkinson’s disease and mediates death in Parkinson’s disease models. J. Neurosci. 35, 10731–10749 (2015).


Hill, R. et al. TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT. Nat. Commun. 8, 14687 (2017).


McMahon, S. B., Van Buskirk, H. A., Dugan, K. A., Copeland, T. D. & Cole, M. D. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 94, 363–374 (1998).


Deleu, L., Shellard, S., Alevizopoulos, K., Amati, B. & Land, H. Recruitment of TRRAP required for oncogenic transformation by E1A. Oncogene 20, 8270–8275 (2001).


Martinez, E. et al. Human STAGA complex is a chromatin-acetylating transcription coactivator that interacts with pre-mRNA splicing and DNA damage-binding factors in vivo. Mol. Cell. Biol. 21, 6782–6795 (2001).


Brand, M., Yamamoto, K., Staub, A. & Tora, L. Identification of TATA-binding protein-free TAFII-containing complex subunits suggests a role in nucleosome acetylation and signal transduction. J. Biol. Chem. 274, 18285–18289 (1999).


Ikura, T. et al. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 102, 463–473 (2000).


McMahon, S. B., Wood, M. A. & Cole, M. D. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol. Cell. Biol. 20, 556–562 (2000).


Lang, S. E., McMahon, S. B., Cole, M. D. & Hearing, P. E2F transcriptional activation requires TRRAP and GCN5 cofactors. J. Biol. Chem. 276, 32627–32634 (2001).


Lang, S. E. & Hearing, P. The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone acetyltransferase complex. Oncogene 22, 2836–2841 (2003).


Park, J., Kunjibettu, S., McMahon, S. B. & Cole, M. D. The ATM-related domain of TRRAP is required for histone acetyltransferase recruitment and Myc-dependent oncogenesis. Genes Dev. 15, 1619–1624 (2001).


Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275–282 (2002).


Taylor, S. S. & Kornev, A. P. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem. Sci. 36, 65–77 (2011).


Jura, N. et al. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol. Cell 42, 9–22 (2011).


Murphy, J. M. et al. Molecular mechanism of CCAAT-enhancer binding protein recruitment by the TRIB1 pseudokinase. Structure 23, 2111–2121 (2015).


Ha, B. H. & Boggon, T. J. The crystal structure of pseudokinase PEAK1 (Sugen Kinase 269) reveals an unusual catalytic cleft and a novel mode of kinase fold dimerization. J. Biol. Chem. 293, 1642–1650 (2017).


Patel, O. et al. Structure of SgK223 pseudokinase reveals novel mechanisms of homotypic and heterotypic association. Nat. Commun. 8, 1157 (2017).


Lecointre, C. et al. Dimerization of the pragmin pseudo-kinase regulates protein tyrosine phosphorylation. Structure 26, 545–554 (2018).


Scheeff, E. D., Eswaran, J., Bunkoczi, G., Knapp, S. & Manning, G. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17, 128–138 (2009).


Hari, S. B., Merritt, E. A. & Maly, D. J. Conformation-selective ATP-competitive inhibitors control regulatory interactions and noncatalytic functions of mitogen-activated protein kinases. Chem. Biol. 21, 628–635 (2014).


Han, Y. et al. Structure of human RNase L reveals the basis for regulated RNA decay in the IFN response. Science 343, 1244–1248 (2014).


Huang, H. et al. Dimeric structure of pseudokinase RNase L bound to 2-5A reveals a basis for interferon-induced antiviral activity. Mol. Cell 53, 221–234 (2014).


Shi, F. et al. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl Acad. Sci. USA 107, 7692–7697 (2010).


Zeqiraj, E. et al. ATP and MO25α regulate the conformational state of the STRADα pseudokinase and activation of the LKB1 tumour suppressor. PLOS Biol. 7, e1000126 (2009).


Zeqiraj, E., Filippi, B. M., Deak, M., Alessi, D. R. & van Aalten, D. M. F. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326, 1707–1711 (2009).


Artim, S. C., Mendrola, J. M. & Lemmon, M. A. Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family. Biochem. J. 448, 213–220 (2012).


Xie, T. et al. Structural insights into RIP3-mediated necroptotic signaling. Cell Rep. 5, 70–78 (2013).


Murphy, J. M. et al. Insights into the evolution of divergent nucleotide-binding mechanisms among pseudokinases revealed by crystal structures of human and mouse MLKL. Biochem. J. 457, 369–377 (2014).


Ma, B. et al. ATP-competitive MLKL binders have no functional impact on necroptosis. PLOS ONE 11, e0165983 (2016). This paper reveals that a previously identified ATP-competitive inhibitor of MLKL stabilizes the pseudokinase domain in the DFG-out state. This compound is also found to inhibit RIPK1, while ATP-competitive molecules that bind to MLKL with greater specificity are unable to inhibit necroptosis.


Pearce, L. R., Komander, D. & Alessi, D. R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 11, 9–22 (2010).


Murphy, J. M. et al. A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. Biochem. J. 457, 323–334 (2013). In this study, a wide range of pseudokinases are classified into different classes on the basis of their ability to bind nucleotides and/or cations.


Gee, C. L. et al. A phosphorylated pseudokinase complex controls cell wall synthesis in mycobacteria. Sci. Signal. 5, ra7 (2012).


Zheng, J. et al. 2.2A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr. D Biol. Crystallogr. 49, 362–365 (1993).


Bailey, F. P. et al. The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner. Biochem. J. 467, 47–62 (2015).


Mukherjee, K. et al. CASK functions as a Mg2+-independent neurexin kinase. Cell 133, 328–339 (2008).


Cui, J. et al. Structure of Fam20A reveals a pseudokinase featuring unique disulfide pattern and inverted ATP-binding. eLife 6, e23990 (2017).


Labesse, G. et al. ROP2 from Toxoplasma gondii: a virulence factor with a protein-kinase foldand no enzymatic activity. Structure 17, 139–146 (2009).


Qiu, W. et al. Novel structural and regulatory features of rhoptry secretory kinases in Toxoplasma gondii. EMBO J. 28, 969–979 (2009).


Brady, D. C. et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature 509, 492–496 (2014).


Mendrola, J. M., Shi, F., Park, J. H. & Lemmon, M. A. Receptor tyrosine kinases with intracellular pseudokinase domains. Biochem. Soc. Trans. 41, 1029–1036 (2013).


Ungureanu, D. et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18, 971–976 (2011).


Hammarén, H. M. et al. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc. Natl Acad. Sci. USA 112, 4642–4647 (2015). This paper demonstrates that ATP binding to the JH2 pseudokinase domain of JAK2 is essential for hyperactivation of pathogenic JAK2 mutants.


Bandaranayake, R. M. et al. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19, 754–759 (2012).


Brennan, D. F. et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472, 366–369 (2011).


Cameron, A. J. M. & Cameron, A. J. M. Occupational hazards: allosteric regulation of protein kinases through the nucleotide-binding pocket. Biochem. Soc. Trans. 39, 472–476 (2011).


Dar, A. C. & Shokat, K. M. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu. Rev. Biochem. 80, 769–795 (2011).


Claus, J., Cameron, A. J. M. & Parker, P. J. Pseudokinase drug intervention: a potentially poisoned chalice. Biochem. Soc. Trans. 41, 1083–1088 (2013).


Karoulia, Z., Gavathiotis, E. & Poulikakos, P. I. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer 17, 676–691 (2017).


Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431–435 (2010).


Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010).


Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221 (2010).


Karoulia, Z. et al. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell 30, 485–498 (2016).


Jin, T. et al. RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition. Nat. Comms 8, 1211 (2017).


Zhang, C. et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature 526, 583–586 (2015).


Okimoto, R. A. et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc. Natl Acad. Sci. USA 113, 13456–13461 (2016).


Girotti, M. R. et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 27, 85–96 (2014).


Mendez, A. S. et al. Endoplasmic reticulum stress-independent activation of unfolded protein response kinases by a small molecule ATP-mimic. eLife 4, e05434 (2015).


Papa, F. R., Zhang, C., Shokat, K. & Walter, P. Bypassing a kinase activity with an ATP-competitive drug. Science 302, 1533–1537 (2003).


Korennykh, A. V. et al. The unfolded protein response signals through high-order assembly of Ire1. Nature 457, 687–693 (2009).


Wang, L. et al. Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors. Nat. Chem. Biol. 8, 982–989 (2012).


Ghosh, R. et al. Allosteric inhibition of the IRE1α RNase preserves cell viability and function during endoplasmic reticulum stress. Cell 158, 534–548 (2014).


Waller, D. D. et al. A covalent cysteine-targeting kinase inhibitor of Ire1 permits allosteric control of endoribonuclease activity. Chembiochem 17, 843–851 (2016).


Otto, T. et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15, 67–78 (2009).


Brockmann, M. et al. Small molecule inhibitors of Aurora-A induce proteasomal degradation of N-Myc in childhood neuroblastoma. Cancer Cell 24, 75–89 (2013).


Gustafson, W. C. et al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26, 414–427 (2014).


Claus, J. et al. Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface. eLife 7, e32271 (2018). This study reveals that the HER2 inhibitor lapatinib promotes heterodimerization of HER2 and HER3 through their N-lobes. This study also demonstrates that ATP binding is essential for the allosteric activator function of HER3 and that bosutinib enhances this function.


Wood, E. R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652–6659 (2004).


Qiu, C. et al. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 16, 460–467 (2008).


Huang, Y. et al. Molecular basis for multimerization in the activation of the epidermal growth factor receptor. eLife 5, e14107 (2016).


Liang, S. I. et al. Phosphorylated EGFR dimers are not sufficient to activate Ras. Cell Rep. 22, 2593–2600 (2018).


Dhawan, N. S., Scopton, A. P. & Dar, A. C. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Nature 537, 112–116 (2016). This paper identifies an ATP-competitive small molecule that stabilizes an inactive conformation of KSR2 that is incompatible with heterodimerization with BRAF.


Tokarski, J. S. et al. Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain. J. Biol. Chem. 290, 11061–11074 (2015). This study describes a series of ATP-competitive compounds that inhibit TYK2 signalling by binding to the TYK2 JH2 pseudokinase domain.


Moslin, R. et al. Identification of imidazo[1,2- b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling. Medchemcomm. 8, 700–712 (2017).


Papp, K. et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N. Engl. J. Med. 379,1313–1321 (2018).


Puleo, D. E. et al. Identification and characterization of JAK2 pseudokinase domain small molecule binders. ACS Med. Chem. Lett. 8, 618–621 (2017).


Newton, A. S. et al. JAK2 JH2 fluorescence polarization assay and crystal structures for complexes with three small molecules. ACS Med. Chem. Lett. 8, 614–617 (2017).


Dong, B. & Silverman, R. H. Alternative function of a protein kinase homology domain in 2’, 5’-oligoadenylate dependent RNase L. Nucleic Acids Res. 27, 439–445 (1999).


Jha, B. K. et al. Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity. J. Biol. Chem. 286, 26319–26326 (2011). In this study, activation of RNase L is found to be inhibited by ATP-competitive compounds, including sunitinib and flavonols, such as quercetin.


Chen, D. et al. Overexpression of integrin-linked kinase correlates with malignant phenotype in non-small cell lung cancer and promotes lung cancer cell invasion and migration via regulating epithelial-mesenchymal transition (EMT)-related genes. Acta Histochem. 115, 128–136 (2013).


Yan, Z. et al. Overexpression of integrin-linked kinase (ILK) promotes migration and invasion of colorectal cancer cells by inducing epithelial-mesenchymal transition via NF-κB signaling. Acta Histochem. 116, 527–533 (2014).


Vaynberg, J. et al. Non-catalytic signaling by pseudokinase ILK for regulating cell adhesion. Nat. Commun. 9, 4465 (2018).


Fukuda, K. et al. Biochemical, proteomic, structural, and thermody 347404 namic characterizations of integrin-linked kinase (ILK): cross-validation of the pseudokinase. J. Biol. Chem. 286, 21886–21895 (2011).


Fukuda, K., Gupta, S., Chen, K., Wu, C. & Qin, J. The pseudoactive site of ILK is essential for its binding to α-parvin and localization to focal adhesions. Mol. Cell 36, 819–830 (2009).


Fleckenstein, M. C. et al. A Toxoplasma gondii pseudokinase inhibits host IRG resistance proteins. PLOS Biol. 10, e1001358 (2012).


Reese, M. L. & Boothroyd, J. C. A conserved non-canonical motif in the pseudoactive site of the ROP5 pseudokinase domain mediates its effect on Toxoplasma virulence. J. Biol. Chem. 286, 29366–29375 (2011).


Reese, M. L., Shah, N. & Boothroyd, J. C. The Toxoplasma pseudokinase ROP5 is an allosteric inhibitor of the immunity-related GTPases. J. Biol. Chem. 289, 27849–27858 (2014).


Zhang, H. et al. Structure and evolution of the Fam20 kinases. Nat. Comms 9, 1218 (2018).


Ohren, J. F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192–1197 (2004).


Jia, Y. et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 534, 129–132 (2016).


Calleja, V., Laguerre, M., Parker, P. J. & Larijani, B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLOS Biol. 7, e17 (2009).


Wu, W.-I. et al. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLOS ONE 5, e12913 (2010).


Adrián, F. J. et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95–102 (2006).


Yang, J. et al. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem. Biol. 18, 177–186 (2011).


Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501–506 (2010).


Bono, F. et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 23, 477–488 (2013).


Herbert, C. et al. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell 23, 489–501 (2013).


Freed, D. M. et al. EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics. Cell 171, 683–695 (2017).


Moraga, I. et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell 160, 1196–1208 (2015).


Engel, M. et al. Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. EMBO J. 25, 5469–5480 (2006).


Busschots, K. et al. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. Chem. Biol. 19, 1152–1163 (2012).


Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101–114 (2017).


Jones, L. H. Small-molecule kinase downregulators. Cell Chem. Biol. 25, 30–35 (2017).


Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem. Biol. 25, 67–77 (2018).


Xie, T. et al. Pharmacological targeting of the pseudokinase Her3. Nat. Chem. Biol. 10, 1006–1012 (2014). This study describes a covalent ATP-competitive small molecule that induces degradation of HER3.


Foulkes, D. M. et al. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. Sci. Signal. 11, eaat7951 (2018). This study reveals that compounds previously identified as covalent inhibitors of EGFR and HER2 can also bind to TRIB2 and induce its degradation.


Garrison, J. L., Kunkel, E. J., Hegde, R. S. & Taunton, J. A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum. Nature 436, 285–289 (2005).


Ruiz-Saenz, A. et al. Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum. Oncogene 34, 5288–5294 (2015). In this study, an inhibitor of the Sec61 translocon is found to induce HER3 degradation by specifically disrupting the cotranslational insertion of HER3 into the endoplasmic reticulum membrane.


Jacob, W., James, I., Hasmann, M. & Weisser, M. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress. Cancer Treat. Rev. 68, 111–123 (2018).


Im, S.-A. et al. A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer [abstract]. J. Clin. Oncol. 32 (Suppl. 15), 2519 (2017).


Sequist, L. V. et al. Targeting EGFR and ERBB3 in lung cancer patients: clinical outcomes in a phase I trial of MM-121 in combination with erlotinib [abstract]. J. Clin. Oncol. 30 (Suppl. 15), 7556 (2017).


Sarantopoulos, J. et al. First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against ERBB3, in patients with metastatic or advanced solid tumors [abstract]. J. Clin. Oncol. 32 (Suppl. 15), 11113 (2017).


Meulendijks, D. et al. A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein [abstract]. J. Clin. Oncol. 31 (Suppl. 15), 2522 (2017).


Wakui, H. et al. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 73, 511–516 (2014).


Schoeberl, B. et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 70, 2485–2494 (2010).


Mirschberger, C. et al. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res. 73, 5183–5194 (2013).


Paz-Arez, L. et al. Patritumab plus erlotinib in EGFR wild-type advanced non–small cell lung cancer (NSCLC): part a results of HER3-lung study: topic: EGFR clinical [abstract P3.02b-045]. J. Thorac. Oncol. 12, S1214–S1215 (2017).


Treder, M. et al. Fully human Anti-HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in vitro and in vivo [abstract]. Cancer Res. 68 (Suppl. 9), LB-20 (2008).


Treder, M. et al. Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models (Poster). EJC Suppl. 6, 99 (2008).


Von Pawel, J. et al. Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs) [abstract]. J. Clin. Oncol. 32 (Suppl. 15), 8045 (2014).


Schaefer, G. et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20, 472–486 (2011).


Huang, S. et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 73, 824–833 (2013).


Fayette, J. et al. Randomized phase II study of duligotuzumab (MEHD7945A) versus cetuximab in squamous cell carcinoma of the head and neck (MEHGAN study). Front. Oncol. 6, 232 (2016).


Hill, A. G. et al. Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) versus cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer. Clin. Cancer Res. 24, 2276–2284 (2018).


Hu, S. et al. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res. 75, 159–170 (2015).


Daneshmanesh, A. H. et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 26, 1348–1355 (2012).


Choi, M. Y. et al. Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1. Clin. Lymphoma Myeloma Leuk. 15, S167–S169 (2015).


Nagano, K. et al. Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients. Cancer Med. 2, 972–977 (2013).


Nagano, K. et al. Eph receptor A10 has a potential as a target for a prostate cancer therapy. Biochem. Biophys. Res. Commun. 450, 545–549 (2014).


Taki, S. et al. A novel bispecific antibody against human CD3 and ephrin receptor A10 for breast cancer therapy. PLOS ONE 10, e0144712 (2015).


Damelin, M. et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci. Transl Med. 9, eaag2611 (2017).


Blaum, B. S. et al. Structure of the pseudokinase domain of BIR2, a regulator of BAK1-mediated immune signaling in Arabidopsis. J. Struct. Biol. 186, 112–121 (2014).


Durzynska, I. et al. STK40 is a pseudokinase that binds the E3 ubiquitin ligase COP1. Structure 25, 287–294 (2016).


Mayans, O. et al. Structural basis for activation of the titin kinase domain during myofibrillogenesis. Nature 395, 863–869 (1998).


Bogomolovas, J. et al. Titin kinase is an inactive pseudokinase scaffold that supports MuRF1 recruitment to the sarcomeric M-line. Open Biol. 4, 140041 (2014).


Mukherjee, K., Sharma, M., Jahn, R., Wahl, M. C. & Südhof, T. C. Evolution of CASK into a Mg2+-sensitive kinase. Sci. Signal. 3, ra33 (2010).


Wei, Z. et al. Liprin-mediated large signaling complex organization revealed by the liprin-α/CASK and liprin-α/liprin-β complex structures. Mol. Cell 43, 586–598 (2011).


Stefely, J. A. et al. Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable coenzyme Q biosynthesis. Mol. Cell 57, 83–94 (2015).


Joubert, S., Jossart, C., McNicoll, N. & De Léan, A. Atrial natriuretic peptide-dependent photolabeling of a regulatory ATP-binding site on the natriuretic peptide receptor-A. FEBS J. 272, 5572–5583 (2005).


Grütter, C. et al. Structural characterization of the RLCK family member BSK8: a pseudokinase with an unprecedented architecture. J. Mol. Biol. 425, 4455–4467 (2013).


Jaleel, M., Saha, S., Shenoy, A. R. & Visweswariah, S. S. The kinase homology domain of receptor guanylyl cyclase C: ATP binding and identification of an adenine nucleotide sensitive site. Biochemistry 45, 1888–1898 (2006).


Kawagoe, T. et al. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat. Immunol. 9, 684–691 (2008).


Toms, A. V. et al. Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat. Struct. Mol. Biol. 20, 1221–1223 (2013).


Leroy, E. et al. Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix. Biochem. J. 473, 1579–1591 (2016).


Wolf, J. et al. Structural basis for Pan3 binding to Pan2 and its function in mRNA recruitment and deadenylation. EMBO J. 33, 1514–1526 (2014).


Christie, M., Boland, A., Huntzinger, E., Weichenrieder, O. & Izaurralde, E. Structure of the PAN3 pseudokinase reveals the basis for interactions with the PAN2 deadenylase and the GW182 proteins. Mol. Cell 51, 360–373 (2013).


Schäfer, I. B., Rode, M., Bonneau, F., Schüssler, S. & Conti, E. The structure of the Pan2-Pan3 core complex reveals cross-talk between deadenylase and pseudokinase. Nat. Struct. Mol. Biol. 21, 591–598 (2014).


Jonas, S. et al. An asymmetric PAN3 dimer recruits a single PAN2 exonuclease to mediate mRNA deadenylation and decay. Nat. Struct. Mol. Biol. 21, 599–608 (2014).


Yoshida-Moriguchi, T. et al. SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science 341, 896–899 (2013).


Zhu, Q. et al. Structure of protein O-mannose kinase reveals a unique active site architecture. eLife 5, e22238 (2016).


Nagae, M. et al. 3D structural analysis of protein O-mannosyl kinase, POMK, a causative gene product of dystroglycanopathy. Genes Cells 22, 348–359 (2017).


Kamada, H. et al. Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3. Biochem. Biophys. Res. Commun. 456, 908–912 (2015).


Garner, A. P. et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 73, 6024–6035 (2013).


Freeman, D., Ogbagabriel, S., Rothe, M., Radinsky, R. & Treder, M. Fully human anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors [abstract]. Cancer Res. 68 (Suppl. 9), LB-21 (2008).


Yonesaka, K., Haratani, K., Hirotani, K. & Nakagawa, K. U3-1402, a novel HER3-targeting ADC, and a novel DNA topoisomerase I inhibitor inhibit the growth of non-small cell lung cancer with EGFR mutation [abstract]. Cancer Res. 77 (Suppl. 13), 44 (2017).


Vincent, S. et al. AV-203, a humanized ERBB3 inhibitory antibody inhibits ligand-dependent and ligand-independent ERBB3 signaling in vitro and in vivo [abstract]. Cancer Res. 72 (Suppl. 8), 2509 (2012).


Alsaid, H. et al. Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice. PLOS ONE 12, e0176075 (2017).


Xiao, Z. et al. A potent HER3 monoclonal antibody that blocks both ligand-dependent and -independent activities: differential impacts of PTEN status on tumor response. Mol. Cancer Ther. 15, 689–701 (2016).


Zhang, L. et al. REGN1400, a fully-human ERBB3 antibody, potently inhibits tumor growth in preclinical models, both as a monotherapy and in combination with EGFR or HER2 blockers [abstract]. Cancer Res. 72 (Suppl. 8), 2718 (2012).


Geuijen, C. et al. Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2:HER3 heterodimer [abstract]. Cancer Res. 75 (Suppl. 15), LB-261 (2015).


Yu, J. et al. Cirmtuzumab targets ROR1 to inhibit ibrutinib-resistant, Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia. Blood 128, 2034–2034 (2016).


Hudecek, M. et al. The B cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116, 4532–4541 (2010).


Halford, M. M. et al. A fully human inhibitory monoclonal antibody to the Wnt receptor RYK. PLOS ONE 8, e75447 (2013).

Source link

wordpress autoblog

amazon autoblog

affiliate autoblog

wordpress website

website development

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *